[Medical Newspaper/Daily Newspaper = Reporter Oh In-gyu] IVRA (International Virus Research Alliance), which is increasing its reputation as a collaborative organization for the treatment of COVID-19, received attention by presenting a new medical paradigm centered on the possibility of 'immune treatment' ahead of the Weed Corona era beyond the COVID-19 pandemic.

On the 29th, IVRA successfully held the ‘International Medical Conference on Sharing Hope to Overcome the COVID-19 Pandemic’ at COEX and other online and offline venues.

The event had added meaning with congratulatory remarks by Chungcheongnamdo Province Governor Yang Seung-jo and UNWHD Chairman Mohamed Jinna, the on-site attendance of Korean medical professionals and ambassadors from related countries, and the online participation of medical professionals from over 30 countries.

results obtained by Professor Jang Hong-seok of Seoul St. Mary's Hospital and Seosan Medical Center from treating COVID-19 patients using the high-frequency hyperthermia device ‘REMISSION 1℃’ provided by AdipoLABs were announced, attracting attention.

REMISSION 1℃ raises our body temperature above 40℃ through high-frequency waves, increasing deep heat and necrosis of heat-vulnerable cancer cells while promoting blood circulation and improving immunity. Based on this, it was certified as a medical device that treats cancer and relieves pain, and has attracted the attention of medical officials at major domestic and international exhibitions.

In this study, two Filipino men were treated twice over two days and then tested for PCR. The results were negative.

As a result of measuring CT values before and after treatment for 20 domestic patients, the average value of the E gene increased from 23.66 before treatment to 32.63 after treatment, and the average value of the RdRP S gene increased from 24.07 before treatment to 33.18 after treatment. In addition, statistically significant results were obtained, with the average value of the N gene before treatment increasing from 25.22 to 33.24 after treatment.

For reference, a CT value of about 35 to 40 is the standard for distinguishing between positive and negative. If it is lower than this value, it is judged positive, and if it is higher than this value, it is judged negative. Therefore, even if the test is positive, the lower the CT value, the faster the virus replicates and the higher the spread.

IVRA Vice Chairman Kim Sun-man, who presented as a speaker, said, “There is a disadvantage in the sample size of treatment cases, but considering the global trend of setting the negative standard to a CT value of 29.5 or less, it is significant that the result was 32 or higher.” “If we expand it globally, we can eliminate the contagiousness of mild COVID patients and asymptomatic COVID-positive people and allow them to return to their daily lives at an early stage,” he emphasized.

Yoo Seung-mo, IVRA Chairman

CEO Han Sung-ho said, “Despite the internal and external economic difficulties caused by the COVID-19 pandemic, REMISSION 1℃ has improved the health of many patients.” He added, “Hyperthermia treatment has increased immunity and achieved meaningful results in treating the COVID-19 virus. “We hope that this donation will serve as an opportunity to prove the effectiveness of immunotherapy for many patients infected with the virus.”

Meanwhile, Mr. Han Sung-ho, CEO of Adipo Labs, who serves as the head of the IVRA cooperation team, received a great response by announcing plans to provide 21 units of the high-frequency hyperthermia device, REMISSION 1℃, free of charge to member countries.

Chairman Yoo Seung-mo emphasized, “We hope to completely solve one part of our life history through research on various viruses, not just the coronavirus,” and added, “In particular, we will be able to create a new beginning through research using electronic medicine.”

In the future, IVRA plans to increase cases based on well-designed protocols and continue research with international scholars through fund creation.

IVRA Chairman Yoo Seung-mo (Chairman of the Health and Health Subcommittee of the Chungnam Regional Economic and Diplomacy Strategy Committee) met with reporters and said, “COVID-19 is not a problem limited to one country, and no matter how much we solve it, mutations will continue.”, “Today’s event, which confirms the possibility of treatment through immunity rather than the existing diagnosis and vaccine method, is not just a fruit, but may provide food for the future of Korea,” he said.

출처 : https://www.bosa.co.kr/news/articleView.html?idxno=2159218